Peripheral Nervous System Agents
12
2
4
4
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
16.7%
2 terminated out of 12 trials
66.7%
-19.9% vs benchmark
58%
7 trials in Phase 3/4
25%
1 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (12)
Natural History of Depression, Bipolar Disorder and Suicide Risk
A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in Europe (PLATINUM EU)
A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in the United States
Nebulized Ketamine for the Treatment of Major Depressive Disorder
Oral Aspirin + Ketamine as Adjunct to Oral Antidepressant Therapy for Depression
Natural Killer Cell (CYNK-001) Infusions in Adults with AML
Rescue Quadratus Lumborum Blocks for Post-cesarean Pain
Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma
Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM
Evaluation of Abdominal Wall Block With Liposomal Bupivacaine for Post-Operative Analgesia in Donor Nephrectomy
Determination of Minimum Effective Volume of Local Anesthetic in Patients Undergoing Ultrasound-Guided Infraclavicular Approach for Brachial Plexus Blockade
Transversus Abdominis Plan Block, Ultrasound or Laparoscopic?